X4 PHARMACEUTICALS, INC Gain (Loss) on Disposition of Intangible Assets
X4 PHARMACEUTICALS, INC (XFOR) reported Gain (Loss) on Disposition of Intangible Assets of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfIntangibleAssets · last filed 2026-03-17
- X4 PHARMACEUTICALS, INC gain (loss) on disposition of intangible assets for the quarter ending 2025-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC gain (loss) on disposition of intangible assets for the quarter ending 2025-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC gain (loss) on disposition of intangible assets for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC gain (loss) on disposition of intangible assets for the quarter ending 2025-03-31 was $0.00.
- X4 PHARMACEUTICALS, INC gain (loss) on disposition of intangible assets for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- X4 PHARMACEUTICALS, INC gain (loss) on disposition of intangible assets for fiscal 2024 was $105.00M.
- X4 PHARMACEUTICALS, INC gain (loss) on disposition of intangible assets for fiscal 2023 was $0.00.
- X4 PHARMACEUTICALS, INC gain (loss) on disposition of intangible assets for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Disposition of Intangible Assets 3 month | Gain (Loss) on Disposition of Intangible Assets 6 month | Gain (Loss) on Disposition of Intangible Assets 9 month | Gain (Loss) on Disposition of Intangible Assets 12 month | Gain (Loss) on Disposition of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $105.00M derived: sum of 4 quarters · filed 2026-03-17 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $105.00M derived: sum of 3 quarters · filed 2026-03-17 | $105.00M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $105.00M derived: sum of 2 quarters · filed 2025-11-05 | $105.00M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $105.00M 10-Q · filed 2025-08-08 | $105.00M 10-Q · filed 2025-08-08 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-17 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 | $509.00K 10-K · filed 2023-03-21 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-21 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $0.00 derived: sum of 2 quarters · filed 2023-03-21 | $0.00 10-K · filed 2023-03-21 | ||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |||
| 2019-12-31 | $104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$3.90M derived: sum of 2 quarters · filed 2022-03-17 | -$3.90M 10-K · filed 2022-03-17 | ||
| 2019-09-30 | -$4.00M 10-Q · filed 2020-11-05 | -$4.00M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $0.00 derived: sum of 2 quarters · filed 2021-03-19 | $0.00 10-K · filed 2021-03-19 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |